By Lina Irawan 
In a striking testament to their unconventional approach, Candid Health co-founder Doug Proctor once spun his laptop to reveal a serene backdrop of wild horses grazing in upstate New York during an initial Zoom call. This imagery served as a fitting, understated flex for two entrepreneurs who have meticulously built one of healthcare’s most compelling infrastructure companies while deliberately sidestepping the bustling, often homogenous, Bay Area startup ecosystem. Their founders, Proctor and CEO Nick Perry, maintain a distinctive, no-frills persona, as Perry himself described it: "glasses and black T-shirts," a deliberate sartorial choice that underscores their focus on substance over Silicon Valley spectacle.
This unique philosophy has clearly resonated with investors, as Candid Health has just concluded a monumental $120 million Series D funding round, an exclusive revelation by Fortune. The round was spearheaded by Sixth Street Growth, a prominent global investment firm known for its strategic investments in high-growth companies. Existing institutional heavyweights, including Oak HC/FT, 8VC, and Y Combinator, also emphatically reinvested, signaling profound confidence in Candid’s trajectory and market leadership. This latest infusion of capital dramatically triples Candid’s projected valuation for 2025, a clear indicator of its accelerating market dominance and disruptive potential. The funding arrives on the heels of an astonishing 190% year-over-year growth in annual recurring revenue (ARR), showcasing robust commercial traction in a critical sector. This Series D round is the latest in a rapid succession of successful capital raises, following a $52.5 million Series C just 18 months prior, which itself built upon a $29 million Series B secured only six months before that. Cumulatively, these rounds propel Candid Health’s total capital raised beyond an impressive $219 million, cementing its status as a heavily backed innovator in the health tech space.
Candid Health’s core mission addresses one of the most persistent and pervasive inefficiencies in the American healthcare system: medical billing. The company effectively assumes the entire billing operation for healthcare providers, liberating doctors and their staff from a labyrinthine administrative burden. The current landscape is notoriously complex, with every single insurer—totaling over 1,000 distinct entities—possessing its own idiosyncratic rulebook for how a claim must be meticulously filled out. Compounding this complexity, most providers are still reliant on archaic billing software, often built in the early 2000s, ill-equipped to navigate the intricate, ever-evolving requirements of thousands of different payers. The consequences of even minor errors, such as a misplaced comma or an incorrect code, are significant: claims are "kicked back," leading to delayed payments, increased administrative costs, and often, either the patient or the provider absorbing the financial loss. Candid Health steps into this void, replacing this error-prone, manual process with sophisticated AI agents and a dynamic rules engine. This proprietary system is meticulously trained on the submission quirks and specific requirements of over 1,000 payers, ensuring that claims are submitted correctly and efficiently the very first time, drastically reducing denials and accelerating payment cycles.
The genesis of Candid Health lies in the shared experience of its co-founders, Nick Perry and Doug Proctor, who first crossed paths at Palantir. There, Perry spearheaded critical healthcare initiatives, while Proctor dedicated his expertise to developing complex defense and intelligence systems. Both recognized that revenue cycle management (RCM)—the intricate process by which healthcare providers receive payment for their services—was fundamentally a data integration challenge, remarkably similar to the complex problems Palantir was engineered to solve, simply applied to the specific domain of medical billing. Their Palantir background imbued them with a profound understanding of how to wrangle vast, disparate datasets and apply advanced analytical tools to achieve operational efficiency.
Perry highlights that Candid’s impressive growth has been almost entirely organic, a rare feat for a company attracting such substantial venture capital. "We’ve grown by word of mouth," he stated, emphasizing that Candid had invested virtually nothing in traditional marketing efforts until this recent funding round. This organic expansion is a powerful testament to the efficacy of their product and the tangible value it delivers to providers. According to Perry, the business has seen phenomenal growth rates on a run rate basis in recent years, expanding 6x, then 5x, and most recently 2.5x. Furthermore, their net revenue retention (NRR) is close to an astounding 200%. This metric is particularly significant for investors, indicating not only minimal customer churn but also that existing clients are significantly increasing their spend with Candid as their own claim volumes scale, underscoring deep product stickiness and expansion opportunities.
The problem Candid Health is tackling is immense, representing a colossal economic burden. Medical billing alone accounts for roughly 1% of the U.S. GDP, a staggering figure that underscores the administrative overhead in the nation’s healthcare system. Per federal data, overall U.S. healthcare spending constitutes approximately 18% of GDP, making it one of the largest sectors of the economy. Industry analysis consistently cites that the country expends an estimated $280 billion annually on healthcare billing administration nationwide. Perry aptly describes this challenge as "worthy and wicked": worthy because its resolution would positively impact nearly every American who has ever contended with an incorrect medical bill, and wicked because truly fixing it demands untangling decades of entrenched, misaligned incentives woven into the very fabric of how providers get paid.
The confidence of investors like Sixth Street Growth is not merely based on projections. Alex Katz of Sixth Street revealed that his firm undertook extensive due diligence, interviewing nearly 40 of Candid Health’s customers before committing to the investment. The feedback, he noted, was "consistently off the charts," painting a picture of unparalleled customer satisfaction and tangible benefits. This qualitative validation is strongly supported by quantitative proof points from Candid’s clients. For instance, Talkiatry, a prominent mental health provider, successfully slashed its manual billing work by an impressive 40% and now boasts an extraordinary 98.3% collection rate of what payers owe. Similarly, Nourish, a nutritional therapy platform, achieved significant growth without needing to expand its billing staff, thanks to Candid’s automation, which processes 96.7% of its claims automatically. These examples highlight Candid’s ability to drive both efficiency and revenue optimization for its diverse client base.
The true disruptive force Candid Health represents isn’t merely superior software; it’s a fundamental shift in economic models. Doug Proctor articulates Candid’s overarching mission as shrinking the medical billing industry itself. By leveraging advanced AI and automation, Candid aims to strip out the manual, often offshore, labor that has historically propped up older, less efficient billing vendors. The savings generated from this increased efficiency are then retained by the healthcare businesses, directly improving their bottom line. This vision pits Candid directly against entrenched legacy systems and practices, promising a leaner, more efficient future for healthcare administration. Despite the rapid growth and substantial funding, CEO Nick Perry remains grounded, not fixated on an immediate IPO. He references Stripe, a highly successful private company, as an example of a desirable path, stating, "Stripe is a very large private company, and they seem great." This perspective suggests a long-term strategy focused on sustainable growth and market dominance rather than a hasty public offering, aligning with their deliberate, outside-the-bubble approach.
Broader Market Activity: Venture Capital, Private Equity, and Funds
Candid Health’s remarkable funding round is set against a backdrop of dynamic activity across the venture capital and private equity landscapes, signaling robust investment interest in transformative technologies and strategic acquisitions.
Venture Deals:
The week saw significant capital flowing into innovative startups across various sectors. Augustus, a New York City-based developer of an AI- and stablecoin-native clearing bank, secured an impressive $180 million in Series B funding. This round, led by Tiger Global with participation from Hummingbird, QED, and others, underscores the growing appetite for infrastructure solutions that promise real-time, global financial transactions through advanced AI and stablecoin technology.
In the robotics space, London-based Humanoid, focused on humanoid industrial robots, raised $152 million in Series A funding. Prime Movers Lab led this substantial round, joined by Schaefer, Bosch, Fubon Financial Holding Venture Capital, and Aglaé Ventures, highlighting the increasing investment in automation that could redefine manufacturing and industrial operations.
Gritt, a San Francisco-based innovator in robotics and AI for construction and infrastructure, announced $32.4 million, combining a $26 million Series A led by Obvious Ventures (with Union Square Ventures and Active Impact Investments) and a preceding $6.4 million seed round. This investment points to the critical need for automation to enhance efficiency and safety in labor-intensive construction sectors.
Bluecore Energy, based in Long Beach, California, garnered $10 million for its development of small modular nuclear reactors designed for floating barge-based power plants. Slauson & Co. led the round, joined by Harlem Capital, Precursor Ventures, LMNT, Visible Hands VC, and Karman Ventures, indicating a strategic bet on novel energy solutions, particularly in the realm of advanced nuclear technology.
From Torino, Italy, ORiS secured €5 million ($5.7 million) in pre-seed funding for its laser-based wireless power transmission systems for space applications. Earlybird and Pitchdrive co-led the round, with participation from Galaxia, Vento, and Piemonte Next Fund, reflecting burgeoning interest in space technology and innovative power delivery mechanisms.
Vikk AI, a Long Beach, California-based developer of an AI-powered legal assistant, raised $4.2 million across pre-seed and seed rounds from individual investors, signaling strong confidence in AI’s potential to transform professional services, particularly the legal sector.
In quantum computing, Photon Queue from Champaign, Illinois, secured $4 million in seed funding led by Playground Global. The company is developing free-space quantum memory devices crucial for advancing quantum computing and networking systems, an area of intense research and investment.
Finally, Zeom, a London, U.K.-based global wealth infrastructure company, raised $2.7 million in pre-seed funding led by Fabric Ventures, with Plug and Play and Tritemius also participating. This investment highlights the ongoing modernization and technological enhancement of wealth management platforms.
Private Equity:
The private equity sector also saw notable movements. Sila, an Alameda, California-based developer of advanced battery materials, raised a significant $300 million in private equity funding. Atreides Management and Sutter Hill Ventures led this round, joined by 8VC, Bessemer Venture Partners, Matrix Partners, T. Rowe Price Associates, and others, underscoring the critical importance of battery technology innovation for electric vehicles and renewable energy storage.
Knox Lane acquired Cross Country Healthcare, a Boca Raton, Florida-based healthcare workforce solutions company, for undisclosed financial terms. This acquisition reflects the continued consolidation and strategic investment in the healthcare services sector, particularly in addressing the critical demand for healthcare staffing.
Funds + Funds of Funds:
Several private equity firms successfully closed new funds, indicating sustained capital availability for future investments. Golden Gate Capital, a San Francisco-based private equity firm, raised $1.5 billion for its seventh fund. This fund will focus on opportunities within industrials, consumer services, and technology & financial services companies, continuing their established investment strategy.
TruArc Partners, a New York City-based private equity firm, successfully closed its fifth fund at $1.2 billion. This capital is earmarked for investments in business services and specialty manufacturing companies, reflecting their sector-specific expertise.
Lastly, Avenue Growth Partners, a Washington, D.C.-based growth equity firm, raised $155 million for its second fund. This fund will specifically target vertical technology companies, signaling a focused approach to investing in software and tech solutions tailored for specific industries.
These diverse funding activities underscore a robust investment landscape, with significant capital being deployed across a spectrum of innovative technologies and strategic acquisitions, all contributing to a dynamic and evolving global economy.
